Atika Capital Management LLC Sells 26,200 Shares of Abivax SA Sponsored ADR $ABVX

Atika Capital Management LLC decreased its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 47.6% during the 1st quarter, HoldingsChannel.com reports. The fund owned 28,800 shares of the company’s stock after selling 26,200 shares during the period. Atika Capital Management LLC’s holdings in Abivax were worth $3,207,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in ABVX. Nan Fung Trinity HK Ltd. lifted its holdings in Abivax by 11.8% in the fourth quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock valued at $15,288,000 after acquiring an additional 12,000 shares during the period. Total Clarity Wealth Management Inc. acquired a new position in shares of Abivax during the 4th quarter worth approximately $1,247,000. Tudor Investment Corp ET AL purchased a new stake in Abivax in the 3rd quarter valued at approximately $2,792,000. Brummer Multi Strategy AB purchased a new stake in Abivax in the 4th quarter valued at approximately $1,939,000. Finally, Harbor Capital Advisors Inc. acquired a new stake in Abivax during the 4th quarter valued at $1,193,000. 47.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ABVX has been the topic of several recent research reports. Guggenheim restated a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Piper Sandler boosted their target price on shares of Abivax from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Citigroup reiterated an “outperform” rating on shares of Abivax in a report on Tuesday, June 2nd. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Finally, HC Wainwright restated a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $152.50.

Abivax Price Performance

ABVX opened at $131.16 on Friday. The stock has a market capitalization of $11.43 billion, a price-to-earnings ratio of -25.17 and a beta of 0.87. The business has a 50-day moving average of $117.77 and a two-hundred day moving average of $118.20. Abivax SA Sponsored ADR has a 12 month low of $65.67 and a 12 month high of $148.83.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. Equities research analysts anticipate that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.